Clene (NASDAQ: CLNN), together with its wholly owned subsidiary, Clene Nanomedicine Inc., is advancing its lead candidate CNM-Au8®, a unique and needed oral treatment for amyotrophic lateral sclerosis (“ALS”), toward a potential FDA accelerated approval. “Clene’s technology targets mitochondrial dysfunction, a novel approach to neurodegenerative diseases, and key FDA meetings in the coming months could be major valuation catalysts for investors… Clene is preparing to initiate a confirmatory Phase 3 ALS trial in the first half of 2026, with a separate MS (multiple sclerosis) program in late-stage development,” reads a recent article. “For investors, Clene’s value lies in its multiple shots on goal: regulatory catalysts in both ALS and MS, ongoing data generation, and a novel therapeutic platform. While clinical-stage biotechs carry inherent risks, the company’s unique approach could significantly shorten its path to commercialization and generate early revenue from a patient population with limited options… Clene’s differentiated technology and advancing clinical programs position it as a company to watch with important investment potential in the evolving neurodegenerative therapy space.”
To view the full article, visit https://ibn.fm/6ebD4
About Clene Inc.
Clene (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.Clene.com.
NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com
InvestorWire is powered by IBN
